We have developed a unique capability to train and predict models from incomplete data. The technology can be used to link large, easy to acquire, databases with small, hard to acquire datasets. Generated models can be used to design, predict and identify errors.
Our algorithms have been wrapped up into our core Alchemite™ engine, enabling a number of software solutions, allowing easy integration in internal workflows or making use of on-demand cloud compute via fully hosted version.
read more about Alchemite
Given a fragmented dataset the algorithm can learn the underlying correlations to estimate the missing knowledge of how candidate drugs act on proteins and therefore help clients to design new drug cocktails to activate the right proteins to cure disease
The million commercially available materials are characterized by hundreds of properties Our technology learns the underlying correlations to estimate the missing properties and propose a material with the target properties
The first commercially availble product Alchemite™, has been specifically built to work with sparse data and is capable of learning from datasets as little as 0.05% complete.
The algorithm has proven commercial applications in materials design and drug discovery. Trained models can be used for predictions, error detection and parameter optimisation (design).
Intellegens is a spin-out from the University of Cambridge that has developed a unique Artificial Intelligence (AI) method for training neural networks from incomplete data sets. The technique, developed in the Department of Physics, has been applied in drug discovery and material design but as the technique is generic it can be applied to many domains where there is big, incomplete data.
Gareth Conduit has a track record of applying artificial intelligence to solve real-world problems, with research contracts held with companies spanning from materials science to healthcare. Gareth holds an academic position at the University of Cambridge and is a Fellow of Gonville & Caius College.
Ben is an expert in big data and cloud based platforms who has delivered full-stack, commercial solutions to numerous clients in scientific, retail and health sectors. Ben has worked with several startups, large corporates and public sector clients.
Tom recently completed his PhD at the University of Cambridge. Tom is leading the application of our novel deep learning approaches to a wide variety of industrial applications, alongside the development of our internal suite of tools and algorithms.
PhD in Mathematics from the University of York. Robert is leading the development of our platform to integrate and optimise our new algorithms in a scalable, secure and robust manner.
Graham was co-founder and VP Engineering at BlueGnome, a specialist in the screening of genetic abnormalities associated with developmental delay, cancer and infertility, which was acquired by US giant Illumina in 2012.
Elaine has worked as an early-stage tech investment manager since 2001. She has extensive experience in all stages of the investment process including due diligence, financial modelling, deal negotiation and investment management.
Biorelate and Intellegens secure InnovateUK funding
Assay imputation with deep learning
Design of alloy for direct laser deposition
Modern methods in drug discovery IPT
Presentation on Streamlining Drug Discovery
Novel deep learning drug discovery platform gets £1 million innovation boost
AI in advanced materials at Engineering Materials Live
Optibrium and Intellegens Collaboration
10 Most Innovative Deep Learning Solution Providers 2018
Materials validation and imputation with neural network
Full stack developer to work closely with the founding team to develop a platform to deliver the technology. Developing a web based interface to the underlying algorithms, backed by a cloud provider allowing on demand building of neural networks that will be made available via API or downloadable, containerized packages.
More details
SEND CV
See how our unique AI can solve real world problems
